射血分数轻度降低的心力衰竭患者应用钠-葡萄糖共转运蛋白2抑制剂的研究进展

doi:10.12114/j.issn.1007-9572.2022.0067

中国全科医学 ›› 2022, Vol. 25 ›› Issue (21): 2680-2685.DOI: 10.12114/j.issn.1007-9572.2022.0067

所属专题：心力衰竭最新文章合集；心血管最新文章合集

射血分数轻度降低的心力衰竭患者应用钠-葡萄糖共转运蛋白2抑制剂的研究进展

安东¹^,², 李树仁²^,^*(), 罗飞², 郝潇²

1．075000　河北省张家口市，河北北方学院研究生院
2．050000　河北省石家庄市，河北省人民医院心内一科

收稿日期:2022-01-25 修回日期:2022-03-14 出版日期:2022-07-20 发布日期:2022-05-19
通讯作者: 李树仁
安东，李树仁，罗飞，等.射血分数轻度降低的心力衰竭患者应用钠-葡萄糖共转运蛋白2抑制剂的研究进展[J].中国全科医学，2022，25（21）：2680-2685. [www.chinagp.net]
作者贡献：安东负责文献/资料收集、整理、分析，撰写论文；李树仁进行文章的构思与设计，负责文章的质量控制及审校，对文章整体负责、监督管理；罗飞、郝潇进行结果分析与解释；郝潇进行论文的修订。

Research Progress of Sodium-glucose-cotransporter-2 Inhibitors in Patients with Heart Failure with Mildly Reduced Ejection Fraction

Dong AN¹^,², Shuren LI²^,^*(), Fei LUO², Xiao HAO²

1. Graduate School of Hebei North University, Zhangjiakou 075000, China
2. Department of Cardiovascular Internal Medicine, Hebei General Hospital, Shijiazhuang 050000, China

Received:2022-01-25 Revised:2022-03-14 Published:2022-07-20 Online:2022-05-19
Contact: Shuren LI
About author:
AN D, LI S R, LUO F, et al. Research progress of sodium-glucose-cotransporter-2 inhibitors in patients with heart failure with mildly reduced ejection fraction[J]. Chinese General Practice, 2022, 25 (21) : 2680-2685.

分享到

摘要/Abstract

摘要： 钠-葡萄糖共转运蛋白2抑制剂即SGLT2抑制剂，最初是作为降糖药而开发的，现已被证明其可降低伴/不伴有动脉粥样硬化性心血管疾病（ASCVD）的2型糖尿病（T2DM）患者的心力衰竭住院（HFH）和心血管死亡风险。EMPEROR-Preserved实验研究评估了SGLT2抑制剂（恩格列净）对射血分数保留的心力衰竭（HFpEF）患者的临床疗效，结果表明，其临床效果可进一步扩大到射血分数轻度降低的心力衰竭（HFmrEF）患者中。虽然SGLT2抑制剂使降低心力衰竭发病率和预防心力衰竭恶化进入到新时代，但仍应继续寻找SGLT2抑制剂改善症状的关键机制，以保护患者免受心力衰竭致命进展的影响。本文就HFmrEF患者应用SGLT2抑制剂治疗进行综述，以期为HFmrEF患者的治疗提供理论指导。

关键词: 心力衰竭, 钠-葡萄糖共转运蛋白2抑制剂, 射血分数轻度降低的心力衰竭, 治疗结果, 综述

Abstract:

Sodium-glucose-cotransporter-2 (SGLT2) inhibitors originally developed as hypoglycemic agents, have been shown to reduce type 2 atherosclerotic cardiovascular disease (ASCVD) with or without heart failure hospitalization (HFH) and cardiovascular mortality risk in patients with diabetes mellitus (T2DM) . The just-concluded EMPEROR-Preserved trial evaluated the clinical efficacy of an SGLT2 inhibitor (empagliflozin) in patients with heart failure with preserved ejection fraction (HFpEF) and the results showed that its clinical effect could be further extended to heart failure mildly reduced ejection fraction (HFmrEF) patients. Although SGLT2 inhibitors have ushered in a new era of reducing HF incidence and preventing HF exacerbation, the search for key mechanisms by which SGLT2 inhibitors improve symptoms should continue to protect heart failure patients from the fatal progression of heart failure disease. This paper reviews the application of SGLT2 inhibitors in the treatment of HFmrEF patients, in order to provide theoretical guidance for the treatment of HFmrEF patients.

Key words: Heart failure, Sodium-glucose transporter 2 inhibitors, Heart failure with mildly reduced ejection fraction, Treatment outcome, Review

安东,李树仁,罗飞,等. 射血分数轻度降低的心力衰竭患者应用钠-葡萄糖共转运蛋白2抑制剂的研究进展[J]. 中国全科医学, 2022, 25(21): 2680-2685. DOI: 10.12114/j.issn.1007-9572.2022.0067.
Dong AN,Shuren LI,Fei LUO, et al. Research Progress of Sodium-glucose-cotransporter-2 Inhibitors in Patients with Heart Failure with Mildly Reduced Ejection Fraction[J]. Chinese General Practice, 2022, 25(21): 2680-2685. DOI: 10.12114/j.issn.1007-9572.2022.0067.

参考文献 58

[1]	IKONOMIDIS I, ABOYANS V, BLACHER J，et al. The role of ventricular-arterial coupling in cardiac disease and heart failure：assessment，clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases，European Association of Cardiovascular Imaging，and Heart Failure Association[J]. Eur J Heart Fail，2019，21（4）：402-424. DOI：10.1002/ejhf.1436.
[2]	FONAROW G C. Diabetes medications and heart failure：recognizing the risk[J]. Circulation，2014，130（18）：1565-1567.
[3]	SHARMA A, PAGIDIPATI N J, CALIFF R M，et al. Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus：lessons learned and future directions[J]. Circulation，2020，141（10）：843-862. DOI：10.1161/CIRCULATIONAHA.119.041022.
[4]	ZINMAN B, WANNER C, LACHIN J M，et al. Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes[J]. N Engl J Med，2015，373（22）：2117-2128.
[5]	SHARMA A, WU J, EZEKOWITZ J A，et al. Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure[J]. ESC Heart Fail，2020，7（1）：274-278. DOI：10.1002/ehf2.12528.
[6]	NEAL B, PERKOVIC V, MAHAFFEY K W，et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med，2017，377（7）：644-657. DOI：10.1056/NEJMc1712572.
[7]	WIVIOTT S D, RAZ I, BONACA M P，et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med，2019，380（4）：347-357. DOI：10.1056/NEJMoa1812389.
[8]	CANNON C P, PRATLEY R, DAGOGO-JACK S，et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. N Engl J Med，2020，383（15）：1425-1435. DOI：10.1056/NEJMoa2004967.
[9]	BHATT D L, SZAREK M, PITT B，et al. Sotagliflozin in patients with diabetes and chronic kidney disease[J]. N Engl J Med，2021，384（2）：129-139. DOI：10.1056/NEJMoa2030186.
[10]	ZANNAD F, COWIE M R. VERTIS-CV：more evidence that sodium glucose cotransporter 2 inhibition brings rapid and sustained heart failure benefit[J]. Circulation，2020，142（23）：2216-2218. DOI：10.1161/CIRCULATIONAHA.120.050512.
[11]	KRAMER C K, YE C, CAMPBELL S，et al. Comparison of new glucose-lowering drugs on risk of heart failure in type 2 diabetes：a network meta-analysis[J]. JACC Heart Fail，2018，6（10）：823-830. DOI：10.1016/j.jchf.2018.05.021.
[12]	GRANT P J, COSENTINO F. The 2019 ESC Guidelines on diabetes，pre-diabetes，and cardiovascular diseases developed in collaboration with the EASD：new features and the'Ten Commandments'of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino，the Task Force chairmen[J]. Eur Heart J，2019，40（39）：3215-3217. DOI：10.1093/eurheartj/ehz687.
[13]	PACKER M, BUTLER J, ZANNAD F，et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction：emperor-preserved trial[J]. Circulation，2021，144（16）：1284-1294. DOI：10.1161/CIRCULATIONAHA.121.056824.
[14]	DEWAN P, SOLOMON S D, JHUND P S，et al. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF[J]. Eur J Heart Fail，2020，22（7）：1247-1258. DOI：10.1002/ejhf.1867.
[15]	BHATT D L, SZAREK M, STEG P G，et al. Sotagliflozin in patients with diabetes and recent worsening heart failure[J]. N Engl J Med，2021，384（2）：117-128. DOI：10.1056/NEJMoa2030183.
[16]	SOLOMON S D, CLAGGETT B, LEWIS E F，et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction[J]. Eur Heart J，2016，37（5）：455-462. DOI：10.1093/eurheartj/ehv464.
[17]	SOLOMON S D, DE BOER R A, DEMETS D，et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction：rationale and design of the DELIVER trial[J]. Eur J Heart Fail，2021，23（7）：1217-1225. DOI：10.1002/ejhf.2249.
[18]	LEE M M Y, BROOKSBANK K J M, WETHERALL K，et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes，or prediabetes，and heart failure with reduced ejection fraction （SUGAR-DM-HF）[J]. Circulation，2021，143（6）：516-525. DOI：10.1161/CIRCULATIONAHA.120.052186.
[19]	NEUEN B L, YOUNG T, HEERSPINK H J L，et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes：a systematic review and meta-analysis[J]. Lancet Diabetes Endocrinol，2019，7（11）：845-854. DOI：10.1016/S2213-8587(19)30256-6.
[20]	SHIM C Y, SEO J, CHO I，et al. Randomized，controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus：the IDDIA trial[J]. Circulation，2021，143（5）：510-512. DOI：10.1161/CIRCULATIONAHA.120.051992.
[21]	DíAZ-RODRíGUEZ E, AGRA R M, FERNÁNDEZÁ L，et al. Effects of dapagliflozin on human epicardial adipose tissue：modulation of insulin resistance，inflammatory chemokine production，and differentiation ability[J]. Cardiovasc Res，2018，114（2）：336-346. DOI：10.1093/cvr/cvx186.
[22]	MAZIDI M, REZAIE P, GAO H K，et al. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus：a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients[J]. J Am Heart Assoc，2017，6（6）：e004007. DOI：10.1161/JAHA.116.004007.
[23]	MCMURRAY J J V, SOLOMON S D, INZUCCHI S E，et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med，2019，381（21）：1995-2008. DOI：10.1056/NEJMoa1911303.
[24]	SCHNEIDER M P, RAFF U, KOPP C，et al. Skin sodium concentration correlates with left ventricular hypertrophy in CKD[J]. J Am Soc Nephrol，2017，28（6）：1867-1876. DOI：10.1681/ASN.2016060662.
[25]	LAMBERS HEERSPINK H J, DE ZEEUW D, WIE L，et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes[J]. Diabetes Obes Metab，2013，15 （9）：853-862. DOI：10.1111/dom.12127.
[26]	HALLOW K M, HELMLINGER G, GREASLEY P J，et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis[J]. Diabetes Obes Metab，2018，20（3）：479-487. DOI：10.1111/dom.13126.
[27]	LOPASCHUK G D, USSHER J R, FOLMES C D，et al. Myocardial fatty acid metabolism in health and disease[J]. Physiol Rev，2010，90（1）：207-258. DOI：10.1152/physrev.00015.2009.
[28]	ZHANG L Y, JASWAL J S, USSHER J R，et al. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy[J]. Circ Heart Fail，2013，6（5）：1039-1048.
[29]	NEUBAUER S. The failing heart—an engine out of fuel[J]. N Engl J Med，2007，356（11）：1140-1151.
[30]	ABOUEZZEDDINE O F, KEMP B J, BORLAUG B A，et al. Myocardial energetics in heart failure with preserved ejection fraction[J]. Circ Heart Fail，2019，12（10）：e006240. DOI：10.1161/CIRCHEARTFAILURE.119.006240.
[31]	DICK S A, EPELMAN S. Chronic heart failure and inflammation：what do we really know? [J]. Circ Res，2016，119（1）：159-176. DOI：10.1161/CIRCRESAHA.116.308030.
[32]	BRIASOULIS A, ANDROULAKIS E, CHRISTOPHIDES T，et al. The role of inflammation and cell death in the pathogenesis，progression and treatment of heart failure[J]. Heart Fail Rev，2016，21（2）：169-176. DOI：10.1007/s10741-016-9533-z.
[33]	LEE H C, SHIOU Y L, JHUO S J，et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats[J]. Cardiovasc Diabetol，2019，18（1）：45. DOI：10.1186/s12933-019-0849-6.
[34]	HEERSPINK H J L, PERCO P, MULDER S，et al. Canagliflozin reduces inflammation and fibrosis biomarkers：a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease[J]. Diabetologia，2019，62（7）：1154-1166. DOI：10.1007/s00125-019-4859-4.
[35]	LENG W L, WU M X, PAN H，et al. The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus[J]. Ann Transl Med，2019，7（18）：429. DOI：10.21037/atm.2019.09.03.
[36]	LEE T M, CHANG N C, LIN S Z. Dapagliflozin，a selective SGLT2 inhibitor，attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts[J]. Free Radic Biol Med，2017，104：298-310.
[37]	KANG S A, VERMA S, HASSANABAD A F，et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts：novel translational clues to explain EMPA-REG OUTCOME results[J]. Can J Cardiol，2020，36（4）：543-553. DOI：10.1016/j.cjca.2019.08.033.
[38]	GRUBIC ROTKVIC P, CIGROVSKI BERKOVIC M, BULJ N，et al. Minireview：are SGLT2 inhibitors heart savers in diabetes? [J]. Heart Fail Rev，2020，25（6）：899-905.
[39]	CAI X L, YANG W J, GAO X Y，et al. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients：a meta-analysis[J]. Obesity （Silver Spring），2018，26（1）：70-80. DOI：10.1002/oby.22066.
[40]	PEREIRA M J, ERIKSSON J W. Emerging role of SGLT-2 inhibitors for the treatment of obesity[J]. Drugs，2019，79（3）：219-230. DOI：10.1007/s40265-019-1057-0.
[41]	LEE P C, GANGULY S, GOH S Y. Weight loss associated with sodium-glucose cotransporter-2 inhibition：a review of evidence and underlying mechanisms[J]. Obes Rev，2018，19（12）：1630-1641. DOI：10.1111/obr.12755.
[42]	SATTAR N. Revisiting the links between glycaemia，diabetes and cardiovascular disease[J]. Diabetologia，2013，56（4）：686-695. DOI：10.1007/s00125-012-2817-5.
[43]	CANNON C P, PERKOVIC V, AGARWAL R，et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c，including those with HbA1c <7%：results from the CREDENCE trial[J]. Circulation，2020，141（5）：407-410. DOI：10.1161/CIRCULATIONAHA.119.044359.
[44]	MATTHEWS V B, ELLIOT R H, RUDNICKA C，et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2[J]. J Hypertens，2017，35（10）：2059-2068. DOI：10.1097/HJH.0000000000001434.
[45]	SANO M. A new class of drugs for heart failure：SGLT2 inhibitors reduce sympathetic overactivity[J]. J Cardiol，2018，71（5）：471-476. DOI：10.1016/j.jjcc.2017.12.004.
[46]	BYRNE N J, PARAJULI N, LEVASSEUR J L，et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure[J]. JACC Basic Transl Sci，2017，2（4）：347-354.
[47]	VERMA S, GARG A, YAN A T，et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes：an important clue to the EMPA-REG OUTCOME trial? [J]. Diabetes Care，2016，39（12）：e212-213.
[48]	LIM V G, BELL R M, ARJUN S，et al. SGLT2 inhibitor，canagliflozin，attenuates myocardial infarction in the diabetic and nondiabetic heart[J]. JACC Basic Transl Sci，2019，4（1）：15-26. DOI：10.1016/j.jacbts.2018.10.002.
[49]	RAGGI P, GADIYARAM V, ZHANG C，et al. Statins reduce epicardial adipose tissue attenuation independent of lipid lowering：a potential pleiotropic effect[J]. J Am Heart Assoc，2019，8（12）：e013104. DOI：10.1161/JAHA.119.013104.
[50]	IBORRA-EGEA O, SANTIAGO-VACAS E, YURISTA S R，et al. Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes[J]. JACC Basic Transl Sci，2019，4（7）：831-840. DOI：10.1016/j.jacbts.2019.07.010.
[51]	SATO T, AIZAWA Y, YUASA S，et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume[J]. Cardiovasc Diabetol，2018，17（1）：6. DOI：10.1186/s12933-017-0658-8.
[52]	ZHOU B, TIAN R. Mitochondrial dysfunction in pathophysiology of heart failure[J]. J Clin Invest，2018，128（9）：3716-3726. DOI：10.1172/JCI120849.
[53]	LI C G, ZHANG J, XUE M，et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart[J]. Cardiovasc Diabetol，2019，18（1）：15. DOI：10.1186/s12933-019-0816-2.
[54]	UTHMAN L, HOMAYR A, JUNI R P，et al. Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor α-stimulated human coronary arterial endothelial cells[J]. Cell Physiol Biochem，2019，53（5）：865-886. DOI：10.33594/000000178.
[55]	PATEL A R, KUVIN J T, PANDIAN N G，et al. Heart failure etiology affects peripheral vascular endothelial function after cardiac transplantation[J]. J Am Coll Cardiol，2001，37（1）：195-200. DOI：10.1016/s0735-1097(00)01057-3.
[56]	LI H L, SHIN S E, SEO M S，et al. The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels[J]. Life Sci，2018，197：46-55. DOI：10.1016/j.lfs.2018.01.032.
[57]	DONNAN J R, GRANDY C A, CHIBRIKOV E，et al. Comparative safety of the sodium glucose co-transporter 2 （SGLT2） inhibitors：a systematic review and meta-analysis[J]. BMJ Open，2019，9（1）：e022577. DOI：10.1136/bmjopen-2018-022577.
[58]	SHIN S J, CHUNG S, KIM S J，et al. Effect of sodium-glucose co-transporter 2 inhibitor，dapagliflozin，on renal renin-angiotensin system in an animal model of type 2 diabetes[J]. PLoS One，2016，11（11）：e0165703. DOI：10.1371/journal.pone.0165703.

射血分数轻度降低的心力衰竭患者应用钠-葡萄糖共转运蛋白2抑制剂的研究进展

Research Progress of Sodium-glucose-cotransporter-2 Inhibitors in Patients with Heart Failure with Mildly Reduced Ejection Fraction

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 58

相关文章 15

编辑推荐

Metrics

留言

[1]	姚裕忠, 马晓骏, 宋懽, 钟瑜. 基于"全专精准管理"的糖尿病"1358模式"对社区糖尿病患者的管理效果研究[J]. 中国全科医学, 2023, 26(34): 4308-4314.
[2]	王旭, 魏戌, 朱立国, 冯天笑, 王志鹏, 师彬. 医工结合的中医手法治疗脊柱退行性疾病疗效机制研究：思路与前景[J]. 中国全科医学, 2023, 26(33): 4118-4124.
[3]	辛功恺, 丛欣, 袁磊, 程悦彤, 倪翠萍, 张巍巍, 張平平, 刘宇. 失智症老年人综合评估工具的研究进展[J]. 中国全科医学, 2023, 26(33): 4103-4109.
[4]	彰金, 丁治国, 祁烁, 李颖, 李伟强, 张媛媛, 周通. 血清甲状腺激素水平与心力衰竭患者住院期间预后的相关性研究[J]. 中国全科医学, 2023, 26(33): 4125-4129.
[5]	张思宇, 周郁秋, 杜晓慧, 王正君. 精神病未治期及其早期干预的研究进展[J]. 中国全科医学, 2023, 26(33): 4110-4117.
[6]	李茜, 张云淑, 严保平, 王健, 马燕娟, 王媛, 秦英杰, 那龙, 任智勇, 孙俊伟, 邓怀丽, 马宏筠, 曲雪慧, 周楠, 司天梅. 注射用利培酮微球（Ⅱ）治疗急性期精神分裂症患者的疗效及安全性研究[J]. 中国全科医学, 2023, 26(32): 4007-4012.
[7]	孟江涛, 杨思宇, 孙蕾, 雷瑞宁, 赵晓霞. 弥散张量成像联合运动诱发电位评估脑梗死偏瘫患者运动功能预后价值的研究进展[J]. 中国全科医学, 2023, 26(32): 4098-4102.
[8]	王佳欣, 赵亚利. 国内外医疗团队合作评估工具系统综述[J]. 中国全科医学, 2023, 26(31): 3951-3962.
[9]	苑喜微, 南月敏. 线粒体融合蛋白2的结构和功能及其在肝脏疾病中作用机制的研究进展[J]. 中国全科医学, 2023, 26(30): 3841-3846.
[10]	马艳艳, 任付先, 王宇, 高登峰. （中性粒细胞+单核细胞）/淋巴细胞比值对心力衰竭患者住院死亡的预测价值研究[J]. 中国全科医学, 2023, 26(30): 3791-3796.
[11]	肖雨倩, 白艳杰, 王岩, 陈淑颖, 陈丽敏, 孙可心, 万俊. 线粒体转移在脑卒中后认知障碍中的研究进展[J]. 中国全科医学, 2023, 26(30): 3833-3840.
[12]	卫梦雨, 王佳佳, 张莹莹, 李春阳, 李建生. 阻塞性睡眠呼吸暂停患者报告结局测评工具研究现状分析[J]. 中国全科医学, 2023, 26(30): 3725-3733.
[13]	张振东, 蔡斌, 王宏伟, 乔增勇. 肠道菌群及其代谢产物苯乙酰谷氨酰胺在慢性心力衰竭患者中的变化研究[J]. 中国全科医学, 2023, 26(29): 3665-3673.
[14]	刘煜, 岳婷, 杨东宇, 赵中亭, 杨吉勃, 朱田田. 自噬在类风湿关节炎发病机制中的研究进展[J]. 中国全科医学, 2023, 26(29): 3710-3714.
[15]	蒲瑜, 张吉翔, 董卫国. 铁死亡与炎症性肠病的研究进展[J]. 中国全科医学, 2023, 26(29): 3698-3703.